|
1
|
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.
|
J Clin Oncol
|
2001
|
4.97
|
|
2
|
Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth.
|
Mol Cell Biol
|
1997
|
3.76
|
|
3
|
Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology.
|
J Clin Oncol
|
2001
|
3.06
|
|
4
|
The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors.
|
Cancer Res
|
2001
|
2.14
|
|
5
|
Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.
|
J Clin Oncol
|
1987
|
2.12
|
|
6
|
Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival.
|
Ann Oncol
|
2003
|
2.08
|
|
7
|
Redefining the target: chemotherapeutics as antiangiogenics.
|
J Clin Oncol
|
2001
|
1.84
|
|
8
|
The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era.
|
Ann Oncol
|
2003
|
1.83
|
|
9
|
Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide.
|
Oncogene
|
2000
|
1.57
|
|
10
|
Monoclonal antibody identification and characterization of a Mr 43,000 membrane glycoprotein associated with human breast cancer.
|
Cancer Res
|
1986
|
1.53
|
|
11
|
Colonic adenomas in asymptomatic women with a history of breast cancer.
|
Am J Gastroenterol
|
1993
|
1.44
|
|
12
|
Taxanes in the treatment of breast cancer: a prodigy comes of age.
|
Cancer Invest
|
1999
|
1.19
|
|
13
|
Inhibition of proliferation and induction of apoptosis by doxycycline in cultured human osteosarcoma cells.
|
J Lab Clin Med
|
1997
|
1.15
|
|
14
|
Effects of doxycycline on in vitro growth, migration, and gelatinase activity of breast carcinoma cells.
|
J Lab Clin Med
|
1995
|
1.14
|
|
15
|
The fertility of patients with clinical stage I testis cancer managed by nerve sparing retroperitoneal lymph node dissection.
|
J Urol
|
1994
|
1.12
|
|
16
|
Cancer cell-derived interleukin 1alpha contributes to autocrine and paracrine induction of pro-metastatic genes in breast cancer.
|
Biochem Biophys Res Commun
|
2000
|
1.10
|
|
17
|
A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy.
|
Blood
|
1996
|
1.07
|
|
18
|
The role of chemotherapy for metastatic breast cancer.
|
Hematol Oncol Clin North Am
|
1999
|
1.01
|
|
19
|
Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment.
|
J Clin Oncol
|
1998
|
1.01
|
|
20
|
Monoclonal antibody storage conditions, and concentration effects on immunohistochemical specificity.
|
J Histochem Cytochem
|
1983
|
1.01
|
|
21
|
Effects of doxycycline on human prostate cancer cells in vitro.
|
Cancer Lett
|
1998
|
0.98
|
|
22
|
A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group.
|
Ann Oncol
|
2011
|
0.94
|
|
23
|
Relationship between platinum-DNA adducts in leukocytes of patients with advanced germ cell cancer and survival.
|
Clin Cancer Res
|
1996
|
0.94
|
|
24
|
MAX2--a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials.
|
Eur J Cancer
|
2004
|
0.93
|
|
25
|
Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial.
|
J Clin Oncol
|
2004
|
0.90
|
|
26
|
Effects of doxycycline on cancer cells in vitro and in vivo.
|
Adv Dent Res
|
1998
|
0.89
|
|
27
|
Quercetin down-regulates signal transduction in human breast carcinoma cells.
|
Biochem Biophys Res Commun
|
1995
|
0.88
|
|
28
|
A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer.
|
Ann Oncol
|
2002
|
0.88
|
|
29
|
Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment.
|
Ann Oncol
|
2005
|
0.88
|
|
30
|
Myeloid progenitor cell proliferation and mobilization effects of BB10010, a genetically engineered variant of human macrophage inflammatory protein-1alpha, in a phase I clinical trial in patients with relapsed/refractory breast cancer.
|
Blood Cells Mol Dis
|
1998
|
0.87
|
|
31
|
Effects of high dose raloxifene in selected patients with advanced breast carcinoma.
|
Cancer
|
2000
|
0.86
|
|
32
|
Clonal dominance detected in metastases but not primary tumors of retrovirally marked human breast carcinoma injected into nude mice.
|
Clin Exp Metastasis
|
1994
|
0.85
|
|
33
|
A new marker of maturation in the cervix: the estrogen-regulated 24K protein.
|
Obstet Gynecol
|
1986
|
0.84
|
|
34
|
Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
|
Oncology (Williston Park)
|
2001
|
0.84
|
|
35
|
Selection bias in clinical trials.
|
Breast Dis
|
2001
|
0.82
|
|
36
|
Lactoferrin: affinity purification from human milk and polymorphonuclear neutrophils using monoclonal antibody (II 2C) to human lactoferrin, development of an immunoradiometric assay using II 2C, and myelopoietic regulation and receptor-binding characteristics.
|
Blood Cells
|
1986
|
0.82
|
|
37
|
Heterogeneity among germ cell tumors of the testis.
|
Semin Oncol
|
1985
|
0.82
|
|
38
|
Fertility considerations in nerve-sparing retroperitoneal lymph-node dissection.
|
World J Urol
|
1994
|
0.82
|
|
39
|
Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group.
|
J Clin Oncol
|
1999
|
0.82
|
|
40
|
Effects of tetracyclines on angiogenesis in vitro.
|
Cancer Lett
|
2000
|
0.81
|
|
41
|
Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial.
|
J Clin Oncol
|
1989
|
0.80
|
|
42
|
A phase II trial of high dose epirubicin in patients with advanced breast carcinoma.
|
Cancer
|
2000
|
0.80
|
|
43
|
Establishment in long term culture of megakaryocytic leukemia cells (EST-IU) from the marrow of a patient with leukemia and a mediastinal germ cell neoplasm.
|
Cancer Res
|
1986
|
0.80
|
|
44
|
Combined anthracycline-taxane regimens in the adjuvant setting.
|
Semin Oncol
|
2001
|
0.79
|
|
45
|
Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: an Eastern Cooperative Oncology Group study.
|
J Clin Oncol
|
1997
|
0.79
|
|
46
|
Steroid hormone receptors in human breast cancer.
|
Adv Cancer Res
|
1983
|
0.79
|
|
47
|
Flow cytometry derived DNA content of the primary lesions of advanced germ cell tumours.
|
Int J Androl
|
1987
|
0.79
|
|
48
|
Should we dream the impossible dream? The meaning of long-term survival in metastatic breast cancer.
|
J Clin Oncol
|
1996
|
0.79
|
|
49
|
Coordinated increase in activities of the signal transduction enzymes PI kinase and PIP kinase in human cancer cells.
|
Life Sci
|
1994
|
0.78
|
|
50
|
An estrogen-regulated protein in normal and malignant endometrium.
|
J Steroid Biochem
|
1986
|
0.78
|
|
51
|
Methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic breast cancer. A phase II trial of the Hoosier Oncology Group.
|
Cancer
|
1991
|
0.78
|
|
52
|
DNA content as a prognostic index in gestational trophoblastic neoplasia.
|
Gynecol Oncol
|
1989
|
0.78
|
|
53
|
Synergism of taxol and gallium nitrate in human breast carcinoma cells: schedule dependency.
|
Oncol Res
|
1994
|
0.78
|
|
54
|
Presence of an estrogen-regulated protein in endometrial cancer.
|
Obstet Gynecol
|
1985
|
0.78
|
|
55
|
Toward checkmate: biology and breast cancer therapy for the new millennium.
|
Invest New Drugs
|
1999
|
0.78
|
|
56
|
Tandem autotransplantation for the treatment of metastatic breast cancer.
|
J Clin Oncol
|
1995
|
0.78
|
|
57
|
Regulation of signal transduction.
|
Adv Enzyme Regul
|
1995
|
0.78
|
|
58
|
Effects of vitamin D3 on proliferation of cancer cells in vitro.
|
Cancer Lett
|
1997
|
0.78
|
|
59
|
Effects of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) on megakaryocytopoiesis in human bone marrow.
|
Exp Hematol
|
1996
|
0.77
|
|
60
|
High-dose chemotherapy in breast cancer -- the perils of history uncontrolled.
|
Medscape Womens Health
|
2000
|
0.77
|
|
61
|
Combined anti-microtubule therapy: a phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer.
|
Ann Oncol
|
2002
|
0.77
|
|
62
|
5-Azacytidine (NSC 102816) in refractory germ cell tumors. A phase II trial of the Eastern Cooperative Oncology Group.
|
Invest New Drugs
|
1994
|
0.76
|
|
63
|
Analysis of phorbol ester stimulated human megakaryocyte development.
|
Blood
|
1988
|
0.76
|
|
64
|
Why big lies matter: lessons from the Bezwoda affair.
|
Medscape Womens Health
|
2000
|
0.76
|
|
65
|
A seat at the table.
|
Clin Breast Cancer
|
2001
|
0.75
|
|
66
|
High-dose carboplatin and mitoxantrone with autologous bone marrow support in the treatment of advanced breast cancer.
|
Am J Clin Oncol
|
1993
|
0.75
|
|
67
|
All therapy is targeted therapy: the future of systemic therapy.
|
Clin Breast Cancer
|
2001
|
0.75
|
|
68
|
Hormones 'R' us.
|
Clin Breast Cancer
|
2002
|
0.75
|
|
69
|
Synergistic action of taxol with tiazofurin and methotrexate in human breast cancer cells: schedule-dependence.
|
Life Sci
|
1994
|
0.75
|
|
70
|
Characterization of multiple 12p rearrangements in testicular germ cell tumor cell line 833K and its subclone 64CP by chromosome microdissection.
|
Cancer Genet Cytogenet
|
1998
|
0.75
|
|
71
|
A retroviral vector expressing human interferon gamma upregulates MHC antigen expression in human breast cancer and leukemia cell lines.
|
Cancer Gene Ther
|
1994
|
0.75
|
|
72
|
Phase II trial of vindesine in adenocarcinoma of the lung.
|
Cancer Treat Rep
|
1984
|
0.75
|
|
73
|
Binding of insulin-like growth factors to Tera-2 human embryonal carcinoma cells during differentiation.
|
Cancer Res
|
1991
|
0.75
|
|
74
|
The future of clinical research in breast cancer: challenges.
|
Clin Breast Cancer
|
2000
|
0.75
|
|
75
|
A tale of two cities: Oxford and Bethesda.
|
Clin Breast Cancer
|
2001
|
0.75
|
|
76
|
Unusual distribution of chromosome 12 in a testicular germ-cell tumor cell line (833K) and its cisplatin-resistant derivative (64CP9).
|
Cancer Genet Cytogenet
|
1993
|
0.75
|
|
77
|
Breast cancer 1984: state of the art.
|
Indiana Med
|
1984
|
0.75
|
|
78
|
Monoclonal antibody (II2C) to human lactoferrin inactivates the myelopoietic suppressive effect of human lactoferrin in vitro.
|
Exp Hematol
|
1986
|
0.75
|
|
79
|
What do we mean by targeted therapy?
|
Clin Breast Cancer
|
2001
|
0.75
|
|
80
|
Phase II trial of vindesine in patients with squamous cell cancer of the head and neck.
|
Am J Clin Oncol
|
1984
|
0.75
|
|
81
|
Initial characterization of a human megakaryocytic leukemia cell line, EST-IU.
|
Prog Clin Biol Res
|
1986
|
0.75
|
|
82
|
The future of clinical research in breast cancer: opportunities.
|
Clin Breast Cancer
|
2000
|
0.75
|